Management Team

Judith Kelleher-Andersson, Ph.D.
President and Chief Executive Officer (CEO), Director
Dr. Kelleher-Andersson has over twenty years of experience developing small-molecule, central nervous system therapeutics in the biotechnology industry. Prior to founding Neuronascent, she was Director of Drug Development and Research at Neuralstem, Inc., Centaur Pharmaceuticals and Cortex Pharmaceuticals, Inc. She headed the Alzheimer’s disease program in collaboration with Astra-Zeneca while at Centaur, and successfully brought a small-molecule agent to pre-nomination status. She invented a depression therapeutic that completed Phase IIb, while at Neuralstem. Dr. Kelleher-Andersson has over 70 US, European and World patents. She received her Ph.D. in biochemistry from University of Missouri-Columbia and completed post-graduate work at UCLA with a Mental Retardation Fellowship and at University of California, San Francisco in the Neurology Dept.

Kenneth Narducy, Ph.D., MBA
Acting COO, Director

Kenneth W Narducy, PhD, MBA, has spent more than 30 years in research and development at biomedical companies (including Abbott and Schering-Plough and the last 20 years with young biomedical companies). Three of the pharma companies in which he was a senior executive were acquired (Oculex by Allergan for $230 million, Centaur by Renovis [now Evotec] for $47 million, and St Charles Pharmaceuticals by Colby Pharmaceutical Company). Dr Narducy earned his PhD in Physical Organic Chemistry from Ohio State University and his MBA in Marketing and Finance from the University of Chicago.

 

 

 


  » Home
» News & Events
» Contact Us
ABOUT US
Management Team
Directors & Advisors
Collaborators
Memberships
TECHNOLOGY
Neurogenesis
Drug Discovery
Intellectual Property
R&D PROGRAMS
Alzheimer's Disease (AD)
Depression
Parkinson's Disease (PD)
Down Syndrome
Ischemia
Hibernation and Ischemia
  © 2016 NeuroNascent, Inc. - All Rights Reserved - Website by TeraMark
This website contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “will,” “expects,” and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this site and involve risks and uncertainties that could cause actual results to differ materially from current expectations.